THE EFFECT OF PATIENT AGE AND SEX ON DECISION-MAKING AROUND AN ALZHEIMER’S DISEASE BLOOD TEST - QUIP II STUDY RESULTS

Q: What was the study analyzing regarding Alzheimer’s blood tests?

The study examined how patient age and sex affected clinical decisions when using a commercially available Alzheimer’s blood biomarker test (PrecivityAD2™) producing APS2, which predicts amyloid PET positivity.

Q: How was clinical decision-making measured in the QUIP II secondary analysis?

Clinical decision-making was recorded by survey before and after blood biomarker testing. The primary composite endpoint captured changes in diagnostic certainty, Alzheimer’s medications, or need for additional brain amyloid evaluation.

Q: Did patient age or sex significantly change the relationship between APS2 and clinical decisions?

No. The APS2 association with the composite endpoint was highly significant overall, but stratification by age or sex showed no significant differences.

Q: What notable finding appeared in the subgroup analysis of the composite endpoint components?

The only significant component-level result was that the magnitude of change in pre- versus post-test diagnostic certainty was lower for Negative APS2 patients aged 60–69 compared with those aged 80 and older.

Sep 29, 2026

Upload by Noah

Blood biomarker tests for Alzheimer’s disease provide accurate, accessible tools to support healthcare provider decisions for patients with mild cognitive impairment or dementia. This secondary analysis of the QUIP II Study assessed how patient age and sex influenced clinical decision-making using a mass spectrometry blood test (PrecivityAD2™) with Amyloid Probability Score 2 (APS2). Among 203 patients, the primary composite endpoint improved markedly post-test, with strong APS2 association, but no significant age- or sex-stratified differences. Subgroup results identified a limited age-related effect only among Negative APS2 patients, supporting clinical utility and generalizability.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

Study objective

Methods and endpoints

Results by age and sex

Subgroup component findings

Clinical implications

654 Innovation in Aging, 2025, Vol. 9, No. S2 Carolina, United States, 4. Advocate Health, Park Ridge, Illinois, United States Blood biomarker (BBM) tests for Alzheimer’s disease represent accurate and accessible tools to aid healthcare providers (HCPs) in the evaluation of patients presenting with signs or symptoms of mild cognitive impairment or dementia. The objective of this analysis was to examine the effects of patient age and sex on clinical decisions using a commercially available mass spectrometry BBM test (PrecivityAD2™ test) yielding the Amyloid Probability Score 2 (APS2), which informs on the likelihood of a positive amyloid PET scan result. This secondary analysis of the QUIP II Study (NCT06025877) included 203 patients (average age 74 years, 53% female) evaluated by 12 HCPs representing 8 outpatient sites. Clinical decision-making was recorded by survey pre-and post-BBM testing. The composite primary endpoint, defined as a change in AD diagnostic certainty, AD medications, or additional brain amyloid evaluation pre- and post-BBM testing, was 75% (p < 0.0001 versus pre-specified threshold of 20% clinically meaningful change) . The relationship between APS2 and composite endpoint was highly significant (p < 0.0001), yet was not significantly different when stratified by age (p = 0.94) or sex (p = 0.337) . In a subgroup analysis of the three individual components of the composite endpoint, the only significant finding was that the magnitude of change in pre-and post-BBMAD diagnostic certainty was lower in the Negative APS2 patients aged 60-69 versus Negative APS2 patients aged 80 and older (p = 0.01), likely related to a lower pre-test AD probability among younger patients. These study results support the usefulness and generalizability of this BBM test in clinical care. Abstract citation ID: igaf122.2234 THE EFFECT OF PATIENT AGE AND SEX ON DECISION-MAKING AROUND AN ALZHEIMER’S DISEASE BLOOD TEST: QUIP II STUDY RESULTS Mark Monane1, Kim Johnson2, Daniel Parker2, Robert Carlile3, Darren Gitelman4, Leslie Jacobs1, Tim West1, and Joel Braunstein1, 1. C2N Diagnostics, St. Louis, Missouri, United States, 2. Duke University, Durham, North Carolina, United States, 3. Palmetto Primary Care Physicians, Summerville, South

FAQs

What was the study analyzing regarding Alzheimer’s blood tests?

The study examined how patient age and sex affected clinical decisions when using a commercially available Alzheimer’s blood biomarker test (PrecivityAD2™) producing APS2, which predicts amyloid PET positivity.

How was clinical decision-making measured in the QUIP II secondary analysis?

Clinical decision-making was recorded by survey before and after blood biomarker testing. The primary composite endpoint captured changes in diagnostic certainty, Alzheimer’s medications, or need for additional brain amyloid evaluation.

Did patient age or sex significantly change the relationship between APS2 and clinical decisions?

No. The APS2 association with the composite endpoint was highly significant overall, but stratification by age or sex showed no significant differences.

What notable finding appeared in the subgroup analysis of the composite endpoint components?

The only significant component-level result was that the magnitude of change in pre- versus post-test diagnostic certainty was lower for Negative APS2 patients aged 60–69 compared with those aged 80 and older.

Sep 29, 2026

Upload by Noah